SG-LAB-MAY

123456789101112131415161718192021222324252627282930313233343536
Across
  1. 3. Control used to simulate treatment
  2. 8. ___ review – assessment by peers
  3. 10. Primary doctor overseeing a trial (abbr.)
  4. 11. Essential code for ethical research (1947)
  5. 13. Documented test procedures (abbr.)
  6. 14. Informed ___ (ethical requirement)
  7. 15. Location for testing new therapies
  8. 17. Common reference point in clinical comparisons
  9. 18. Predefined outcome used to assess a treatment
  10. 19. Type of trial where treatment is concealed
  11. 22. Study conducted without bias
  12. 27. U.S. database of registered trials
  13. 29. Consent must be given ___ (freely)
  14. 30. Common unit in dose measurement
  15. 33. Type of clinical trial that tests a treatment
  16. 34. A request for authorization from FDA to administer an investigational drug or biological product to humans
  17. 35. Acronym for Randomized Controlled Trial (abbr.)
  18. 36. Organization that regulates drugs (abbr.)
Down
  1. 1. Phase ___ – first stage of human testing
  2. 2. Long-term study: follow-___
  3. 4. Subject group not receiving treatment
  4. 5. ___-label – all treatment details visible
  5. 6. James ___ – pioneer of clinical trials
  6. 7. A group or treatment pathway in a clinical trial
  7. 9. Type of assignment that removes bias
  8. 12. Adverse ___ – undesirable effect
  9. 15. Form used for data entry (abbr.)
  10. 16. Clinical research ___ (supports investigators)
  11. 20. Study of how the body processes drugs
  12. 21. Investigator’s Brochure (abbr.)
  13. 23. Trial halted before completion: ___ stop
  14. 24. Ideal trial design: randomized, double-blind, placebo-controlled
  15. 25. Participants are often called ___
  16. 26. Pre-trial testing phase (animal/in vitro)
  17. 28. Small group selected to represent a larger population
  18. 31. Favorable outcome or improvement seen in response to treatment
  19. 32. IRB stands for Institutional ___ Board